Considerations to Improve Patient Outcomes in Early Drug Development

February 17, 2022 | 10:00am EST

Every drug development program must begin with an understanding of how the relevant key stakeholders factor into the development process. It’s not just a matter of courtesy; a comprehensive examination of the roles played by all participants has the potential to produce faster and more concrete results, leading to improved patient outcomes.

Register for this webinar to learn about these and other vital product development considerations, such as:

– Developing a framework for handling multiple endpoints for the drug’s go-to-market label

– Determining the potential of adaptive design for optimizing the trial and evaluating the applicability of various adaptive design approaches

– Key interactions and questions to ask when seeking regulatory input of pivotal study designs


Abie Ekangaki, Ph.D., Vice President, Statistical Consulting; Rupa Doshi, Ph.D., Vice President, Oncology Strategy; Vice President, Regulatory Affairs, Regulatory Professionals, A Division of Premier Research.